Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: EyeDrMike who wrote (5849)	3/10/1998 5:58:00 AM
From: RT	Read Replies (2) \| Respond to of 23519

<<As soon as the FDA and MCA approvals come, the analysts will be forced to restate estimates and upgrade this stock, for the production capacity problems will be over.>> Dr. Mike, The production problem may be over in May, but with the subsequent launch of Viagara, the market for Muse will be adversely affected for several quarters, at the very least. Mike you need to take off your rose colored glasses. Viagara, short term, is going to impact Vivus's sales in a negative way. If Viagara's results turn out to be less than spectacular, then Vivus will benefit long term. RT